Prof. Dr. YILMAZ ÇAPAN

Yayın Ağı

Makaleler 56

1. Silica nanoparticle synthesis by experimental design for drug and gene delivery applications

Ultav G., TONBUL H., ŞAHİN A., ÇAPAN Y.

Journal of Research in Pharmacy , cilt.27, sa.1, ss.12-22, 2023 (Scopus, TRDizin)

2. Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier

Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.66, 2021 (SCI-Expanded, Scopus)

3. Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells

TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.63, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis

YÜCE M., Sert F., Torabfam M., Parlar A., Gurel B., Cakir N., et al.

ANALYTICA CHIMICA ACTA , cilt.1152, 2021 (SCI-Expanded, Scopus)

5. Brain-targeted nanoparticles to overcome the blood-brain barrier

SEKO I., ŞAHİN A., TONBUL H., ÇAPAN Y.

Journal of Pharmaceutical Technolgy , cilt.1, sa.1, ss.26-40, 2020 (Hakemli Dergi)

6. Development of paclitaxel and flurbiprofen co-loaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett-Burman design

Sahin A., Caban-Toktas S., Tonbul H., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.

ISTANBUL JOURNAL OF PHARMACY , cilt.49, sa.3, ss.161-166, 2019 (ESCI, TRDizin)

7. Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer

Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.54, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Nanopharmaceuticals as Drug-Delivery Systems: For, Against, and Current Applications

ÇALIŞ S., ÖZTÜRK ATAR K., ARSLAN F. N., EROĞLU H., ÇAPAN Y.

NANOCARRIERS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY , ss.133-154, 2019 (SCI-Expanded)

9. DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING HPLC METHOD FOR DIFLUCORTOLONE VALERATE AND ISOCONAZOLE NITRATE COMBINATION

Gundogdu S. O., Simsek F., Doganay A., Capan Y.

ACTA POLONIAE PHARMACEUTICA , cilt.76, sa.1, ss.49-58, 2019 (SCI-Expanded, Scopus)

10. Nano-Based Carriers for Brain Drug Delivery

ÖZTÜRK ATAR K., Ozkan M., EROĞLU H., ÇAPAN Y.

CHARACTERIZATION AND BIOLOGY OF NANOMATERIALS FOR DRUG DELIVERY: NANOSCIENCE AND NANOTECHNOLOGY IN DRUG DELIVERY , ss.563-586, 2019 (SCI-Expanded)

11. Synthesis of Small-Sized Mesoporous Silica Nanoparticles by Experimental Design and Characterization for Further Drug Delivery

TONBUL H., Ultav G., AKBAŞ S., Sahin A., AKTAŞ Y., ÇAPAN Y.

LATIN AMERICAN JOURNAL OF PHARMACY , cilt.38, sa.11, ss.2204-2210, 2019 (SCI-Expanded, Scopus)

12. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure

Akbas S., Sahin A., ÇALIŞ S., Oncel H., ÇAPAN Y.

PHARMAZIE , cilt.73, sa.7, ss.369-374, 2018 (SCI-Expanded, Scopus)

13. Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles

Kozlu S., Sahin A., Ultav G., Yerlikaya F., ÇALIŞ S., ÇAPAN Y.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.45, ss.213-219, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides

Yemisci M., Caban S., Fernandez-Megia E., ÇAPAN Y., Couvreur P., DALKARA T.

NEUROTROPHIC FACTORS: METHODS AND PROTOCOLS, 2ND EDITION , cilt.1727, ss.443-454, 2018 (SCI-Expanded, Scopus)

15. Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)

Kozlu S., ŞAHİN A. E., ÇALIŞ S., ÇAPAN Y.

PHARMAZIE , cilt.72, sa.10, ss.568-570, 2017 (SCI-Expanded, Scopus)

16. DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS

YÜCE M., ÇAPAN Y.

ACTA POLONIAE PHARMACEUTICA , cilt.74, sa.2, ss.357-367, 2017 (SCI-Expanded, Scopus)

17. Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells

Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., et al.

JOURNAL OF MICROENCAPSULATION , cilt.34, sa.7, ss.659-666, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery

ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., et al.

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY , cilt.45, sa.8, ss.1657-1664, 2017 (SCI-Expanded, Scopus)

19. Preformulation of Immediate Release Candesartan Cilexetil Tablets Using Full Factorial Experimental Design

YÜCE M., GÜVEN O., KARAHAN S., SARAÇBAŞI O., ÇAPAN Y.

LATIN AMERICAN JOURNAL OF PHARMACY , cilt.35, sa.5, ss.921-930, 2016 (SCI-Expanded, Scopus)

20. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection

Yemisci M., Caban S., Gursoy-Ozdemir Y., Lule S., NOVOA-CARBALLAL R., RIGUERA R., et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM , cilt.35, sa.3, ss.469-475, 2015 (SCI-Expanded, Scopus)

21. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury

Gaudin A., Yemisci M., EROĞLU H., Lepetre-Mouelhi S., Turkoglu O. F., Donmez-Demir B., et al.

NATURE NANOTECHNOLOGY , cilt.9, sa.12, ss.1054-1062, 2014 (SCI-Expanded, Scopus)

22. An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design

KOZLU S., CABAN S., YERLIKAYA F., FERNANDEZ-MEGIA E., NOVOA-CARBALLAL R., RIGUERA R., et al.

PHARMAZIE , cilt.69, sa.5, ss.340-345, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

23. Comparative in vitro studies on PBN loaded nanoparticles prepared by biodegradable chitosan, PLGA polymers and their PEGylated block copolymers

Ozturk K., FERNANDEZ-MEGIA E., NOVOA-CARBALLAL R., RIGUERA R., Yemisci M., GURSOY-OZDEMIR Y., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.24, sa.2, ss.148-152, 2014 (SCI-Expanded, Scopus)

24. Beyine İlaç Taşınması:Truva Atı Teknolojisi

DOĞAN S. S., TOKTAŞ S., ÇAPAN Y.

Hacettepe University Journal of the Faculty of Pharmacy , 2014 (Hakemli Dergi)

25. Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach

Yerlikaya F., Ozgen A., VURAL İ., Guven O., Karaagaoglu E., Khan M. A., et al.

JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.102, sa.10, ss.3748-3761, 2013 (SCI-Expanded, Scopus)

26. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression

OLMEZ S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.

PHARMAZIE , cilt.68, sa.2, ss.110-116, 2013 (SCI-Expanded, Scopus)

27. Beyine İlaç Hedeflendirme Stratejileri

DOĞAN S. S., TOKTAŞ S., ÇAPAN Y.

Hacettepe University Journal of the Faculty of Pharmacy , 2013 (Hakemli Dergi)

28. Formulation and in vitro evaluation of paclitaxel loaded nanoparticles Paklitaksel yüklü nanopartiküllerin formülasyonu ve in vitro incelenmesi

Aygül G., Yerlikaya F., Caban S., VURAL İ., ÇAPAN Y.

Hacettepe University Journal of the Faculty of Pharmacy , cilt.33, sa.1, ss.25-40, 2013 (Scopus)

29. TRANSPORT OF A CASPASE INHIBITOR ACROSS THE BLOOD BRAIN BARRIER BY CHITOSAN NANOPARTICLES

YEMISCI M., GURSOY-OZDEMIR Y., CABAN S., BODUR E., ÇAPAN Y., DALKARA T.

NANOMEDICINE: CANCER, DIABETES, AND CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, PULMONARY AND INFLAMMATORY DISEASES , cilt.508, ss.253-269, 2012 (SCI-Expanded, Scopus)

30. Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides.

Caban S., Capan Y., Couvreur P., Dalkara T.

Methods in molecular biology (Clifton, N.J.) , cilt.846, ss.321-32, 2012 (Scopus)

31. CHARACTERIZATION, CELL PROLIFERATION AND CYTOTOXICITY EVALUATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LOADED POLY (LACTIC-CO-GLYCOLIC ACID) MICROSPHERES

KERİMOĞLU O., ALARÇİN E., Turkoglu M., Dortunc B., Karagoz H., Ulkur E., et al.

NOBEL MEDICUS , cilt.8, sa.1, ss.77-82, 2012 (SCI-Expanded, Scopus)

32. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets

Bozdag-Pehlivan S., Subasi B., VURAL İ., Unlu N., ÇAPAN Y.

Acta Poloniae Pharmaceutica - Drug Research , cilt.68, sa.3, ss.423-433, 2011 (SCI-Expanded, Scopus)

33. Orally disintegrating tablets ii: In vitro and in vivo evaluations Aǧızda daǧılan tabletler ii: In vitro ve in vivo deǧerlendirilmeleri

Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.

Hacettepe University Journal of the Faculty of Pharmacy , cilt.31, sa.1, ss.59-70, 2011 (Scopus)

34. Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(ε-caprolactone) and chitosan nanoparticles

Cirpanli Y., Yerlikaya F., Ozturk K., Erdogar N., Launay M., Gegu C., et al.

Pharmazie , cilt.65, sa.12, ss.867-870, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

35. Orally disintegrating tablets i: Preparation technologies Aǧizda daǧilan tabletler i: Hazirlama teknolojileri

Ölmez S. S., VURAL İ., ŞAHİN S., ERTUĞRUL A., ÇAPAN Y.

Hacettepe University Journal of the Faculty of Pharmacy , cilt.30, sa.2, ss.205-230, 2010 (Scopus)

36. LC-UV Determination of Melatonin from Chitosan Nanoparticles

Yerlikaya F., Aktas Y., ÇAPAN Y.

CHROMATOGRAPHIA , cilt.71, ss.967-970, 2010 (SCI-Expanded, Scopus)

37. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection

KARATAS H., AKTAS Y., GURSOY-OZDEMIR Y., BODUR E., YEMISCI M., CABAN S., et al.

Journal of Neuroscience , cilt.29, sa.44, ss.13761-13769, 2009 (SCI-Expanded, Scopus)

38. ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TAMOXIFEN CITRATE USING NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Yerlikaya F., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.38, sa.1, ss.183-184, 2009 (SCI-Expanded)

39. Microbiological and clinical comparison of chlorhexidine buccoadhesive tablet and chlorhexidine mouthrinse

AKTAŞ A., GIRAY B., ÇAPAN Y., MENEMENLIOGLU D., HAYRAN M., IKINCI G., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.19, sa.5, ss.353-357, 2009 (SCI-Expanded, Scopus)

40. Etodolac loaded poly (lactide-co-glycolide) nanoparticles: Formulation and in vitro characterization Etodolak yüklü poli (Laktid-ko-glikolid) nanopartikülleri: Formülasyon ve i̇n vitro karakter

Çirpanli Y., Robineau C., ÇAPAN Y., ÇALIŞ S.

Hacettepe University Journal of the Faculty of Pharmacy , cilt.29, sa.2, ss.105-114, 2009 (Scopus)

41. Desensitization to allopurinol in a patient with fixed drug eruption

Damadoglu E., Isik S. R., KARAKAYA G., ÇAPAN Y., KALYONCU A. F.

ASTIM ALLERJI IMMUNOLOJI , cilt.7, sa.3, ss.194-197, 2009 (ESCI, TRDizin)

42. Preparation and Characterization of Salmon Calcitonin-biotin Conjugates

ÇETİN M., Youn Y. S., ÇAPAN Y., Lee K. C.

AAPS PHARMSCITECH , cilt.9, sa.4, ss.1191-1197, 2008 (SCI-Expanded, Scopus)

43. Preparation and characterization of BSA-loaded alginate microspheres

ÇETİN M., VURAL İ., ÇAPAN Y., Hincal A. A.

Fabad Journal of Pharmaceutical Sciences , cilt.32, sa.3, ss.103-107, 2007 (Scopus)

44. Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity

Na D. H., Faraj J., Capan Y., Leung K. P., DeLuca P. P.

PHARMACEUTICAL RESEARCH , cilt.24, sa.8, ss.1544-1550, 2007 (SCI-Expanded, Scopus)

45. Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system

Faraj J. A., Dorati R., Schoubben A., Worthen D., Selmin F., Capan Y., et al.

AAPS PHARMSCITECH , cilt.8, sa.1, 2007 (SCI-Expanded, Scopus)

46. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain

KİLİC A. C., Capan Y., Vural I., Gursoy R. N., Dalkara T., CUİNE A., et al.

JOURNAL OF MICROENCAPSULATION , cilt.22, sa.6, ss.633-641, 2005 (SCI-Expanded, Scopus)

47. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor

AKTAŞ Y., ANDRİEUX K., ALONSO M. J., CALVO P., Gursoy R. N., COUVREUR P., et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , cilt.298, sa.2, ss.378-383, 2005 (SCI-Expanded, Scopus)

48. Method Validation in Determination of Mitoxantrone by HPLC

Bozdaǧ S., ÇAPAN Y., VURAL İ., Hincal A. A.

Acta Pharmaceutica Turcica , cilt.46, sa.1, ss.43-47, 2004 (Scopus)

49. Mitoxantrone loaded poly(DL-lactide-co-glycolide) microspheres for treatment of brain tumors I. formulation and release characteristics

Bozdaǧ S., ÇAPAN Y., VURAL İ., Hincal A., DeLuca P.

Technology and Health Care , cilt.10, ss.353-355, 2002 (SCI-Expanded, Scopus)

50. In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine

İKİNCİ G., ÇAPAN Y., ŞENEL S., Alaaddinoglu E., DALKARA T., Hincal A.

Pharmazie , cilt.55, sa.10, ss.762-765, 2000 (SCI-Expanded, Scopus)

51. Formulation and in vitro in vivo investigation of carbamazepine controlled-release matrix tablets

Ikinci G., Capan Y., Senel S., Dalkara T., Hincal A.

PHARMAZIE , cilt.54, sa.2, ss.139-141, 1999 (SCI-Expanded, Scopus)

52. Histological and bioadhesion studies on buccal bioadhesive tablets containing a penetration enhancer sodium glycodeoxycholate

Senel S., Capan Y., Sargon M. F., Giray C. B., Hincal A.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , cilt.170, sa.2, ss.239-245, 1998 (SCI-Expanded, Scopus)

53. In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride

Senel S., Duchene D., Hincal A., Capan Y., Ponchel G.

JOURNAL OF CONTROLLED RELEASE , cilt.51, ss.107-113, 1998 (SCI-Expanded, Scopus)

54. Enhancement of transbuccal permeation of morphine sulfate by sodium glycodeoxycholate in vitro

Senel S., Capan Y., Sargon M. F., Ikinci G., Solpan D., Guven O., et al.

JOURNAL OF CONTROLLED RELEASE , cilt.45, sa.2, ss.153-162, 1997 (SCI-Expanded, Scopus)

55. Formulation and in Vitro–in Vivo Evaluation of Buccoadhesive Morphine Sulfate Tablets

Anlar Ş., ÇAPAN Y., Güven O., GÖĞÜŞ A., DALKARA T., Hincal A.

Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists , cilt.11, sa.2, ss.231-236, 1994 (Scopus)

56. Formulation, Bioavailability, and Pharmacokinetics of Sustained-Release Potassium Chloride Tablets

ŞENEL S., ÇAPAN Y., DALKARA T., İnanç N., Hincal A. A.

Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists , cilt.8, sa.10, ss.1313-1317, 1991 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 36

1. Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin İn Breast Cancer

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., et al.

8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019, cilt.1, ss.184-186, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

2. PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES

TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., et al.

19th InternationalPharmaceutical Technology Symposium-IPTS 2018, 17 - 19 Eylül 2018, (Tam Metin Bildiri)

3. DEVELOPMET AND EVALUATION OF SILICA NANOPARTICLES USING A QUALITY BY DESIGN APPROACH

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.

EUFEPS Annual Meeting 2018, 24 - 26 Mayıs 2018, (Özet Bildiri)

4. IN VITRO EVALUATION OF PACLITAXEL LOADED MESOPOROUS SILICA NANOPARTICLES

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.

EUFEPS Annual Meeting 2018, 24 - 26 Mayıs 2018, (Özet Bildiri)

5. Synthesis and Characterization of Silica Nanoparticles: Obtaining nanoparticles smaller than 100 nm

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., KAYNAK M. S., AKTAŞ Y., et al.

2nd International Gazi Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

6. Transferrine hedeflendirilmiş paklitaksel yüklü PLGA nanopartiküllerinin meme kanserindeki etkinliği

TONBUL H., ŞAHİN A., ÖZTÜRK N., VURAL İ., KAYNAK M. S., ÇAPAN Y.

1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Türkiye, 1 Haziran - 02 Ocak 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges

ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.

GPEN 2016, 9 - 12 Kasım 2016

8. Drug Delivery with Targeted Nanoparticles: in Vitro and in Vivo Evaluation Methods.

ÇAPAN Y.

17th International Pharmaceutical Technology Symposium, 18 - 21 Ekim 2016

9. Intracellular delivery and intraperıtoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method

ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., et al.

18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 Eylül 2016

10. Development and in vitro evaluation of transferrin targeted PLGA nanoparticle

TONBUL H., ŞAHİN A., KAYNAK M. S., ÇAPAN Y.

18th International Pharmaceutical Technology Symposium-IPTS 2016, 19 - 21 Eylül 2016

11. Co Encapsulation Studies of Doxorubicin and Celecoxib in PLGA Nanoparticles

Kozlu S., ŞAHİN A., Sevda Ş., Yerlikaya F., ÇAPAN Y.

18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 Eylül 2916 - 21 Eylül 2016

12. Brain drug delivery

ÇAPAN Y.

International Conference on Advances in the Area of Bioequivalance, Pharmaceutical Technology Symposium, 14 Kasım 2015

13. Particle Size Optimization of Ibuprofen Loaded PLGA Nanoparticles Using Box Behnken Design

ŞAHİN A., Çaban S., AKTAŞ Y., ÇAPAN Y.

AAPS 2015 Annual Meeting, 25 - 29 Ekim 2015

14. Effects of Combined Surfactants in the Formulation of Docetaxel Loaded PLGA Nanoparticles

Abdykerim Kyzy G., Çaban S., ŞAHİN A., ÇAPAN Y.

AAPS Annual Meeting 2015, 25 - 29 Ekim 2015

15. Determination of Critical Parameters of Paclitaxel and Flurbiprofen Co Loaded PLGA Nanoparticles Prepared By Nanoprecipitation

ŞAHİN A., Çaban S., Abdykerim Kyzy G., Yerlikaya F., AKTAŞ Y., ÇAPAN Y.

AAPS Annual Meeting 2015, 25 - 29 Ekim 2015

16. Nanoscale drug delivery systems and the blood-brain barrier

ÇAPAN Y.

17th International Pharmaceutical Technology Symposium, 8 - 10 Eylül 2014

17. Nanoparticular Drug Delivery Systems Pharmaceutical Applications

ÇAPAN Y.

IAEA Regional Training Course on ˝Radiation Synthesis and Characterization of Nanostructures, 8 - 12 Kasım 2010

18. Brain Drug Targetting

ÇAPAN Y.

15th Internetional Pharmaceutical Technology Symposium, 13 - 15 Ekim 2010

19. The importance of particle size analysis: Its role in pharmaceutical development

ÇAPAN Y.

United States Pharmacopeia and Ekin Kimya 4th Science Standards Symposium, 15 Ekim 2010

20. Brain Drug Targeting

ÇAPAN Y.

6th International Biomedical Science and Technology Symposium, 28 Eylül - 02 Ekim 2010

21. Brain Drug Targeting IMPPS-3

ÇAPAN Y.

Third International Meeting On Pharmacy Pharmaceutical Sciences, 9 - 12 Haziran 2010

22. Evaluation of the products with the same formula on the point of pharmaceutical technolgy

ÇAPAN Y.

Turkish Society of Hematology Updating on Hematological Oncology Meeting, 6 - 09 Mayıs 2009

23. Bioavailability Bioequivalance

ÇAPAN Y.

BioInternational 2008, 22 - 24 Ekim 2008

24. Blood Brain Barrier Delivery with Molecular Trojan Horses

ÇAPAN Y.

14th Internetional Pharmaceutical Technology Symposium, 6 - 10 Eylül 2008

25. Perspectives in drug release from micro- and nanoparticulate drug delivery systems

ÇAPAN Y.

14th Internetional Pharmaceutical Technology Symposium, 6 - 10 Eylül 2008

26. Bioavailability and Bioequivalance

ÇAPAN Y.

34. National Haematology Congress, 10 - 11 Ağustos 2008

27. Technological Factors Influencing BA / BE

ÇAPAN Y.

FATUM Symposium on Bioavailability / Bioequivalance and Regulatory Issues, 17 - 18 Mart 2008

28. Recent Advances in Brain Drug Delivery

ÇAPAN Y.

16th International Symposium on Microencapsulation, 09 Eylül 2007

29. BE practice and issues in Turkey

ÇAPAN Y.

Biointernational 2005, 24 - 25 Ekim 2005

30. An overview of dissolution and bioequivalence

ÇAPAN Y.

Hands-On-Dissolution Workshop, 10 - 11 Ekim 2005

31. Nanoparticle technology its Pharmaceutical Applications

ÇAPAN Y.

FIP Meeting, 01 Ocak 2005

32. Preparation and Characterization of Basic Fibroblast Growth Factor (bFGF)-Loaded Microparticulate Drug Delivery Systems,

ÇETİN M., ÇAPAN Y., VURAL İ., GÜRSOY R. N., DALKARA T., Cuine A., et al.

2004 AAPS Annual Meeting and Exposition, Maryland, Amerika Birleşik Devletleri, 31 Ekim 2004, (Tam Metin Bildiri)

36. Preparation and Characterization of Poly (D,L-lactide-co-glycolide) Microspheres For Controlled Release of Poly (L-Lysine) Complexed Plasmid DNA

ÇAPAN Y.

8th Biomedical Science and Technology Symposium, 5 - 08 Eylül 2000

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

982

H-İndeks (WoS)

Atıf (Scopus)

1124

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Proje

Açık Erişim